LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT.US lakewoodamedex.com + Research + Basket
Employees 5
Phone 941 225 2515
Fiscal year end December
IPO Apr 23, 2026
Address 8031 Cooper Creek Blvd., University Park, FL, United States, 34201
0.19
0.00 (-1.85%)
USD · NASDAQ
52-week range
0.17
9.82
Trading at 0% of the 52-week range
Market Cap
462.09K
P/E Ratio
0.00
Forward P/E
0.00
Book Value
2.00
Div. Yield
N/A
% Institutions
6.02%
% Insiders
39.47%

1 Year

-97.8%

3 Year

-97.8%

10 Year

-97.8%
Description

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Actions

Add an action for LABT.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Kelvin Cooper Ph.D. CEO, SVP of Research & Development and Director 1956
Mr. Peter F. Ceccacci CFO & VP of Administration 1955
Dr. Thomas Balzer M.D., Ph.D. Chief Medical Officer & SVP of Clinical Development 1960
Ms. Tara Endress Project Manager & Accounting Manager NA
Daniel Kontoh-Boateng Investor Relations NA

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Marex Group Ltd 48.17K Jun 30, 2026 2.03% $0.00 0.00%
HRT FINANCIAL LLC 44.78K Jun 30, 2026 1.89% $0.00 0.00%
UBS Group AG 4.10K Jun 30, 2026 0.17% $0.00 0.00%
Tower Research Capital LLC 624.00 Jun 30, 2026 0.03% $0.00 0.00%
Advisor Group Holdings, Inc. 138.00 Jun 30, 2026 0.01% $0.00 0.00%
Ronald Blue Trust, Inc. 11.00 Jun 30, 2026 0.00% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Nasdaq Composite Index 43.31K 1.83% ▲ 0.00% Aug 31, 2026
2 Fidelity Extended Market Index 1.49K 0.06% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $462.09K
EBITDA: $-7.26M
Book Value: $2.00
Earnings/Share: $-8.83
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -139.40%
ROE (TTM): -402.84%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-4.05M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 2.37M
Shares Float: 847.66K
% Insiders: 39.47%
% Institutions: 6.02%
Shares Short: 90.04K
Shares Short (Prior Month): 130.72K
Short Ratio: 0.04
Short % Float: 7.39%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-2.51M
R&D
adjust
$-1.26M
Other Operating Expense
adjust
$-4.63K
Operating Income
subtotal
$-3.77M
Other / Non-Operating Items
adjust
$-75.27K
Net Income
subtotal
$-3.85M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about LABT.US!